AFA
NGNE icon

Alta Fundamental Advisers’s Neurogene NGNE Stock Holding History

Alta Fundamental Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,485
Closed -$74.5K – 18
2023
Q2 		$74.5K Buy
+4,485
New +$73.5K 0.04% 13

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alta Fundamental Advisers's NGNE Position: Q3 2023 in Review

Alta Fundamental Advisers sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 4,485 shares — an estimated $74.5K sold.

Alta Fundamental Advisers first reported a position in NGNE in Q2 2023 and held it in 1 quarter. The position peaked at $74.5K in Q2 2023. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

  • Alta Fundamental Advisers reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
  • Alta Fundamental Advisers sold 4,485 Neurogene shares in Q3 2023, an estimated $74.5K.
  • Alta Fundamental Advisers first reported a position in Neurogene in Q2 2023 and held it in 1 quarter.
  • Alta Fundamental Advisers's Neurogene position peaked at $74.5K in Q2 2023.
  • 31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on Alta Fundamental Advisers's 13F filing for Q3 2023, filed 13 Nov 2023.